Central to this transition was the creation of a mouse genome-engineering research program leading to discoveries and techniques for humanizing mouse immune systems.
These proprietary technologies formed the foundation in 2010 of Kymab Ltd. Kymab was conceived as a platform-to-product company, where the first few years were focused on building the platform. Kymab have used this platform to discover novel human antibody therapeutics that it has validated pre-clinically and is now testing the first of these in human clinical trials.
In his academic role, Allan has published widely in high impact journals and is a respected expert in the monoclonal antibody and mouse engineering fields. Previously he was a Howard Hughes Medical Institute Investigator at Baylor College of Medicine (Houston, USA) where he built up one of the biggest transgenic mouse facilities in the USA and also spun out Lexicon Genetics, another successful pharmaceutical company based on mouse genetic technology. Allan is a Fellow of the Royal Society.